Biobeat

Biobeat Analysis

Biobeat is an Israeli-based med-tech startup founded in 2016, specializing in remote patient monitoring with its distinct health-AI technology. The company's AI remote patient monitoring platform measures 13 vital signs and triggers early clinical intervention. Biobeat's innovative approach utilizes disposable short-term chest and long-term wrist monitors, both incorporating a photoplethysmography-based sensor for continuous and accurate patient readings.

Leveraging its automatic, continuous, and noninvasive RPM AI platform, Biobeat has amassed the largest vital-sign database globally, enabling the identification of early patient deterioration through proprietary big-data and health-AI tools.

This aggregated patient health data is securely integrated into Biobeat’s cloud-based patient management platform, ensuring HIPPA and GDPR compliance. The platform features an automated real-time Early Warning Score (EWS) system, incorporating advanced AI algorithms to provide alerts on patient health status and potential deterioration, supporting medical teams in tailored patient care and disease prevention.

Additionally, Biobeat's wearable devices are the first to be FDA-Cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified. The company recently secured an $8.00M Series A investment on March 1, 2020, from the Menomadin Foundation.